Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2019-03-28 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于召开2018年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2018 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on (including the 2018 annual report, audit report, financial statements, and profit distribution plan), registration details, and proxy voting instructions. The document does not contain the actual annual report, financial statements, or audit report, but rather serves as a formal notification to shareholders about the AGM and the matters to be considered. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself. The document length is about 4923 characters, which is consistent with a detailed AGM notice rather than a full annual report or audit report. Therefore, the correct classification is AGM Information (AGM-R).
2019-03-28 Chinese
第四届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the second meeting of the fourth Supervisory Board of the company 福安药业（集团）股份有限公司, held on March 28, 2019. It includes approvals of various reports related to the 2018 fiscal year, such as the Supervisory Board Work Report, Financial Statements, Audit Report, Annual Report, Internal Control Self-Evaluation Report, and others. The document states that these reports are published simultaneously on the China Securities Regulatory Commission designated disclosure website, indicating that the reports themselves are separate documents. The text is relatively short (2723 characters) and primarily serves as a meeting resolution announcement rather than containing the full reports or detailed financial data. Therefore, this document is an announcement of the Supervisory Board meeting resolutions and related approvals, not the reports themselves. This fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain full reports or detailed financial data.
2019-03-28 Chinese
2018年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the fiscal year 2018 of 福安药业（集团）股份有限公司. It contains detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. The text includes an auditor's opinion, basis for the opinion, key audit matters, and responsibilities of management and auditors. The presence of detailed financial data and the auditor's report indicates this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters), and it contains the full audit report and financial statements, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2018
2019-03-28 Chinese
2018年度募集资金实际存放与使用情况的审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the actual deposit and use of raised funds for the year 2018 by 福安药业（集团）股份有限公司. It is issued by an accounting firm (北京永拓会计师事务所) and includes detailed financial data on fundraising, usage, and management of funds, as well as audit opinions. The document references regulatory requirements from the China Securities Regulatory Commission and includes audit opinions on the fundraising usage report. It is not a full annual report but a standalone audit report focused on the fundraising funds' management and usage. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles related to specific financial aspects, excluding full annual reports. The document length and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2018
2019-03-28 Chinese
2019年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast for the period January 1, 2019 to March 31, 2019, indicating expected net profit decline compared to the previous year. It explicitly states that the forecast has not been audited and that detailed data will be disclosed in the 2019 first quarter report. The document is short (825 characters) and serves as an announcement of expected financial results rather than a full interim or quarterly report containing actual financial statements or substantive financial data. Therefore, it is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q1 2019
2019-03-28 Chinese
独立董事2018年度述职报告（马赟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the Year 2018" from a company. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, on-site investigations, and efforts to protect investor rights during the 2018 fiscal year. The content is a narrative report on the independent director's duties and activities rather than a financial report, audit, or regulatory filing. It is not an announcement or a brief notice but a substantive report on management/board activities and oversight. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2019-03-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.